ocr: Source Study Group Induction Post Remission CR Outcome Comments CALGB'37 AML DA Cyclic maintenance 725 12-mo median Standard induction <601 y "3+7" with A/D/P/VCR 31% duration CR >60 y ECOGIS de novo AML DAT HIDACAMSA VS 68% 27% EFS (4 y) in Addition of b-thioguanine; <65y T/A VS allo-BMT HIDAC/AMSA group HIDAC intensibcation ALSG150 de novo AML AD/VP-16 A/D/VP-16 59% 17-mo median survival Addition of VP-16 to <70y "7-3-7" "5-2-5" standard "8+7" MSKCC155 de novo AML IDRA DRA 80% 20-mo median survival darubicin substituted as <60y y "3+5" "2+4": X 2 anthracycline UCLAIO AML D/IDAC HIDAC/mito - ...
